Opaganib

Drug Overview

Opaganib (also known by the brand name Yeliva and code name ABC294640) is a first-in-class, orally bioavailable, small-molecule selective inhibitor of sphingosine kinase-2 (SK2). It is an aryladamantane compound designed to modulate the sphingolipid signaling pathway, which is frequently dysregulated in cancer, inflammation, and viral infections.

In the clinical landscape of March 2026, opaganib is recognized as a versatile host-targeted therapeutic. While it is primarily an investigational antineoplastic agent, its mechanism—which targets host cell components rather than viral proteins—has also made it a prominent candidate for treating severe viral diseases, including COVID-19 and Ebola. In oncology, it is valued for its ability to induce immunogenic cell death (ICD), potentially turning “cold” tumors “hot” and enhancing the efficacy of modern checkpoint inhibitors.

• Generic Name: Opaganib.
• Code Name: ABC294640.
• Drug Class: Sphingosine Kinase-2 (SK2) Inhibitor; Antineoplastic; Antiviral.
• Mechanism: Competitive inhibition of SK2, preventing the formation of pro-survival Sphingosine 1-phosphate (S1P) and inducing apoptosis and autophagy.
• Route of Administration: Oral (Capsule).
• FDA Status: Investigational. As of March 2026, it has received Orphan Drug Designation for cholangiocarcinoma, neuroblastoma, and pancreatic cancer.

What Is It and How Does It Work? (Mechanism of Action)

Opaganib works by flipping a biological “survival switch” in cells. It targets the “sphingolipid rheostat,” a delicate balance between pro-death and pro-growth lipid molecules.

1. The Sphingolipid Rheostat

Cells contain two main competing lipids: Ceramide/Sphingosine (which signal the cell to die) and Sphingosine 1-phosphate (S1P) (which signals the cell to grow and move).

• Inhibiting SK2: Opaganib blocks the SK2 enzyme from converting sphingosine into S1P.
• Tipping the Balance: This causes S1P levels to drop while pro-apoptotic sphingosine and ceramide levels rise, forcing the cancer cell to undergo apoptosis (programmed cell death).

2. Triple-Enzyme Inhibition

Beyond SK2, opaganib has been shown to simultaneously inhibit two other key enzymes in human cells: DES1 (dihydroceramide desaturase) and GCS (glucosylceramide synthase). This triple-action approach leads to the accumulation of dihydroceramides, which triggers autophagy—a process where the cell essentially “eats itself” from the inside.

3. “Host-Directed” Antiviral Activity

Unlike traditional antivirals that attack the virus directly, opaganib targets the human cell components the virus needs to replicate.

• Resisting Mutation: Because it targets the host rather than the virus, it is expected to remain effective against emerging viral variants (like new strains of SARS-CoV-2 or Influenza) that might otherwise develop drug resistance.

FDA Status and Clinical Trials (2024–2026)

As of early 2026, opaganib is in advanced stages of clinical evaluation for several high-unmet-need areas:

1. Oncology

• Cholangiocarcinoma (Bile Duct Cancer): Granted Orphan Drug Designation. A Phase 2a study (NCT03377179) evaluated opaganib alone and in combination with hydroxychloroquine for advanced unresectable cases.
• Prostate Cancer: A Phase 2 trial (NCT04207255) in metastatic castrate-resistant prostate cancer (mCRPC) recently focused on combining opaganib with androgen signaling blockers (like abiraterone or enzalutamide) to overcome treatment resistance. A new Phase 2 study with darolutamide was initiated in February 2025.
• Neuroblastoma: Granted Orphan Drug Designation in August 2024 for pediatric patients.
• Multiple Myeloma: Phase 1b studies have shown it is generally safe and well-tolerated in relapsed/refractory cases.

2. Other Indications

• COVID-19: Evaluated in Phase 2/3 trials for hospitalized patients with moderate-to-severe disease.
• Medical Countermeasures: The U.S. Government is evaluating opaganib as a treatment for Acute Radiation Syndrome (ARS) and chemical/biological threats like Ebola and Sulfur Mustard exposure.

Dosage and Administration Protocols

As an investigational agent, dosage is strictly controlled by clinical trial protocols.

• Administration: Taken orally, usually in capsule form.
• Empty Stomach: Some protocols suggest taking it at least 1 hour before or 2 hours after meals to optimize absorption, though this varies by study.

Safety Profile and Side Effects

In studies involving over 470 participants, opaganib has demonstrated a manageable safety profile.

Common Side Effects:

• Gastrointestinal: Nausea, vomiting, and diarrhea. These are generally mild-to-moderate.
• Hematologic: Decreased neutrophil counts (neutropenia) have been noted, particularly at higher doses in cancer patients.
• Systemic: Fatigue and decreased appetite.

Serious Risks:

• Liver Enzymes: Transient elevations in liver function tests (AST/ALT) may occur, requiring regular monitoring.
• Infection Risk: Due to potential drops in white blood cell counts, patients must be monitored for signs of infection.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, opaganib is being used to study “Radio-protection.” Researchers are investigating how SK2 inhibition can protect healthy Hematopoietic Stem Cells from radiation damage during cancer therapy or after a nuclear accident. In 2026, there is also intense focus on “Venetoclax Re-sensitization.” Recent 2025 in vivo studies showed that adding opaganib to the BCL-2 inhibitor venetoclax could reduce Chronic Lymphocytic Leukemia (CLL) cell counts by 50% in resistant models, suggesting a way to overcome drug resistance in blood cancers.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Baseline Blood Work: Comprehensive CBC and liver function tests (LFTs) are mandatory.
• Cardiovascular Check: Baseline assessment is recommended in some protocols due to the drug’s effect on lipid signaling.

“Do’s and Don’ts” List:

• DO strictly follow the “days on” and “days off” schedule provided by your clinical trial coordinator.
• DO report any “extreme fatigue” or “yellowing of the skin” immediately, as these could signal liver stress.
• DON’T stop taking the medication abruptly if you experience mild nausea; consult your care team for anti-emetic options first.
• DON’T start new herbal supplements, as they may interact with the host-directed metabolic pathways opaganib targets.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Opaganib (ABC294640) is an investigational agent and is not approved by the U.S. FDA for commercial use outside of clinical trials or authorized expanded access programs. Always consult with a qualified oncologist or principal investigator regarding your specific diagnosis and eligibility for research participation.